In this briefing:
- Taisho To Launch Another DHG Pharma Tender
- Global Bottoming Process Continues; Remain Overweight China
1. Taisho To Launch Another DHG Pharma Tender
After the close on 28 February 2019, Taisho Pharmaceutical Holdings (4581 JP)announced it would launch another Tender Offer, this time to purchase up to 21.7% of the Vietnam-listed DHG Pharmaceutical Jsc (DHG VN) a.k.a. Duoc Hau Giang Pharmaceutical JSC.
On 3 July 2018, the company announced that it had received approval from the State Securities Commission (SSC) to raise the foreign ownership limit to 100%, with official disclosure of it going into effect 4 July. Shortly afterwards, Taisho launched a Tender Offer to purchase 7.06% of the shares outstanding of DHG, with the intention to get to 32.00%. Taisho registered to buy more shares last autumn, and bought a further 925,200 shares on 20 February to bring their stake to 34.99%, and now they intend to move to 56.69%.
This next one threatens a much higher minimum pro-ration, BUT it is at the same price as the last one, and while this is at a significant premium to a one-month or three-month average trading price, it is less than a 3.5% premium to Wednesday’s close of VND 116,000/share.
More below the fold.
2. Global Bottoming Process Continues; Remain Overweight China
The MSCI ACWI and ACWI ex-US have managed to break above their respective 200-day moving averages, and are now bumping up against overhead resistance. Supportive of a bottoming global market, cyclical Sectors are emerging as leadership. We examine the technical state of major developed and EM markets and highlight in today’s report and highlight attractive and actionable stocks within the Materials, Manufacturing, and Technology sectors.
Get Straight to the Source on Smartkarma
Smartkarma supports the world’s leading investors with high-quality, timely, and actionable Insights. Subscribe now for unlimited access, or request a demo below.
